Over the years, the perception of inflammatory diseases has changed drastically. The advent of cytokine inhibitors meant great improvement to many patients, especially those suffering from rheumatoid arthritis. However, these treatments remain symptomatic. Together with Janssen Pharmaceutica, world-renowned rheumatologist Lars Klareskog is ready to take the research and treatment of inflammatory joint disease to the next level.
Investing in biotech companies is a capital-intensive and risky business, and it’s no secret that more money and less risk-averse investors are available in the US than in Europe. To keep innovations, companies, and their economic benefits from being transferred to regions outside Europe, many national and international European initiatives are in place. The question remains whether this is sufficient to fundamentally improve Europe’s currently underfunded biotech ecosystem. The biotech investment specialists of V-Bio Ventures take us through Europe’s biotech investment landscape.
Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company will build an atlas of DNA found in the blood, convinced major investors, such as Bill Gates and Jeff Bezos, of the technology’s potential. A whopping $1 billion was gathered in the company’s series B financing round. Yet, do Grail and its technology deserve this huge ticket?
Mosquitoes are carriers of a range of crippling diseases, posing an enormous global health burden. Because current methods based on insecticides are inadequate, new tools are urgently needed. Widely different companies are tackling the problem of mosquito control from very different angles; who will be successful in getting a grip on these tiny flying terrors? A view by V-Bio Ventures.
Over the years, the perception of inflammatory diseases has changed drastically. The advent of cytokine inhibitors meant great improvement to many patients, especially those suffering from rheumatoid arthritis. However, these treatments remain symptomatic. Together with Janssen Pharmaceutica, world-renowned rheumatologist Lars Klareskog is ready to take the research and treatment of inflammatory joint disease to the next level.
Investing in biotech companies is a capital-intensive and risky business, and it’s no secret that more money and less risk-averse investors are available in the US than in Europe. To keep innovations, companies, and their economic benefits from being transferred to regions outside Europe, many national and international European initiatives are in place. The question remains whether this is sufficient to fundamentally improve Europe’s currently underfunded biotech ecosystem. The biotech investment specialists of V-Bio Ventures take us through Europe’s biotech investment landscape.
Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company will build an atlas of DNA found in the blood, convinced major investors, such as Bill Gates and Jeff Bezos, of the technology’s potential. A whopping $1 billion was gathered in the company’s series B financing round. Yet, do Grail and its technology deserve this huge ticket?
Mosquitoes are carriers of a range of crippling diseases, posing an enormous global health burden. Because current methods based on insecticides are inadequate, new tools are urgently needed. Widely different companies are tackling the problem of mosquito control from very different angles; who will be successful in getting a grip on these tiny flying terrors? A view by V-Bio Ventures.